- ISIN
- US6402681083
- CUSIP
- 640268108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 3, 1994
Highlights
- Market Cap
- $1.63B
- Enterprise Value
- $1.58B
- EPS (TTM)
- -$8.64
- Total Revenue (TTM)
- $55.63M
- Gross Profit (TTM)
- $44.58M
- EBITDA (TTM)
- -$121.05M
- Year Range
- $21.02 - $109.00
- Target Price
- $132.83
- ROA (TTM)
- -20.71%
- ROE (TTM)
- -27.44%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NKTR Performance Chart
Nektar Therapeutics (NKTR) is up 55.4% since the beginning of the year. At $66 per share, NKTR is trading 39.7% below its 52-week high of $109. Investors who bought $1,000 worth of NKTR shares 5 years ago would now be looking at an investment worth $263.
Loading charts...
Returns By Period
Nektar Therapeutics (NKTR) has returned 55.39% so far this year and 672.03% over the past 12 months. Over the last ten years, NKTR has returned -11.21% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Nektar Therapeutics
- 1D
- 7.74%
- 1M
- -1.37%
- YTD
- 55.39%
- 6M
- 51.10%
- 1Y
- 672.03%
- 3Y*
- 96.12%
- 5Y*
- -23.46%
- 10Y*
- -11.21%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.15%
- 1Y
- 24.03%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NKTR Monthly Returns History
Based on dividend-adjusted daily data since May 3, 1994, NKTR's average daily return is +0.11%, while the average monthly return is +2.08%. At this rate, an investment would double in approximately 2.8 years.
Historically, 48% of months were positive and 52% were negative. The best month was Jun 2025 with a return of +137.8%, while the worst month was Feb 2023 at -49.3%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, NKTR closed higher 46% of trading days. The best single day was Jun 24, 2025 with a return of +156.3%, while the worst single day was Mar 14, 2022 at -60.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.71% | 84.78% | 4.31% | 18.19% | -23.71% | 1.26% | 55.39% | ||||||
| 2025 | -11.04% | 1.54% | -19.05% | 16.99% | -8.93% | 137.77% | -16.10% | 37.73% | 90.56% | 14.11% | 0.43% | -35.16% | 203.08% |
| 2024 | -4.02% | 30.92% | 31.58% | 56.28% | -13.01% | -2.36% | 8.06% | -4.48% | 1.56% | -8.46% | -4.20% | -18.42% | 64.60% |
| 2023 | 20.35% | -49.26% | -49.07% | 7.03% | -22.89% | -0.84% | -6.85% | 11.05% | 0.10% | -21.26% | 4.48% | 15.31% | -75.00% |
| 2022 | -17.69% | -7.91% | -47.36% | -23.38% | -15.74% | 9.20% | 4.21% | -0.51% | -18.78% | 17.50% | -25.53% | -19.29% | -83.27% |
| 2021 | 15.88% | 15.18% | -11.86% | -1.95% | -7.85% | -5.04% | -7.98% | -1.96% | 16.02% | -15.59% | -25.73% | 19.98% | -20.53% |
Benchmark Metrics
Nektar Therapeutics has an annualized alpha of 14.28%, beta of 1.31, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since May 03, 1994.
- This stock participated in 138.37% of S&P 500 Index downside but only 103.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.28%
- Beta
- 1.31
- R²
- 0.10
- Upside Capture
- 103.49%
- Downside Capture
- 138.37%
Return for Risk
Risk / Return Rank
NKTR ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NKTR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.71 | ||
| Sortino ratioReturn per unit of downside risk | +4.07 | ||
| Omega ratioGain probability vs. loss probability | 1.77 | 1.37 | +0.40 |
| Calmar ratioReturn relative to maximum drawdown | 14.58 | 2.78 | +11.79 |
| Martin ratioReturn relative to average drawdown | 31.29 | 12.44 | +18.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nektar Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nektar Therapeutics was 99.61%, occurring on Nov 28, 2023. The portfolio has not yet recovered.
The current Nektar Therapeutics drawdown is 95.96%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -99.61%Nov 2023 | 5y 8mo | — | 8y 3moMar 2018 - now |
Financial crisis2007–2009 | -95.53%Oct 2008 | 8y 7mo | 9y 2mo | 17y 10moMar 2000 - Jan 2018 |
1998 bear market1998 | -41.10%Oct 1998 | 12mo 3d | 1y 2mo | 2y 2moOct 1997 - Dec 1999 |
1996 bear market1996 | -38.17%Sep 1996 | 4mo 14d | 5mo 23d | 10mo 7dMay 1996 - Mar 1997 |
1995 bear market1995 | -37.78%Apr 1995 | 5mo 26d | 4mo 7d | 10mo 3dOct 1994 - Aug 1995 |
Drawdown Indicators
| NKTR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.61% | -56.78% | -42.83% |
Max Drawdown (1Y)Largest decline over 1 year | -46.54% | -9.10% | -37.44% |
Max Drawdown (3Y)Largest decline over 3 years | -73.20% | -18.90% | -54.30% |
Max Drawdown (5Y)Largest decline over 5 years | -97.76% | -25.43% | -72.33% |
Max Drawdown (10Y)Largest decline over 10 years | -99.61% | -33.92% | -65.69% |
Current DrawdownCurrent decline from peak | -95.96% | -1.80% | -94.16% |
Average DrawdownAverage peak-to-trough decline | -68.35% | -10.71% | -57.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.64% | 2.03% | +19.61% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nektar Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nektar Therapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NKTR relative to other companies in the Biotechnology industry. Currently, NKTR has a P/S ratio of 21.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NKTR in comparison with other companies in the Biotechnology industry. Currently, NKTR has a P/B value of 2.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NKTR
Add Nektar Therapeutics to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NKTR